Urology
Expert guidance on urologic oncology, stone disease, BPH management, incontinence, and minimally invasive surgical approaches.
Recent Discussions
When should multiparametric MRI (mpMRI) be utilized in prostate cancer workup?
Early adopters of prostate mpMRI are unique and always a pleasure to meet. I've learned a great deal from many of them. They’ve moved beyond aiming at a CT density in the pelvis and learned how to use mpMRI sequences to better classify the risk of disease they’re treating. This is in comparison to o...
How do you decide when to refer a patient with metastatic renal cell carcinoma for cytoreductive nephrectomy?
Although dated, two large randomized trials showed a nearly 6 month OS advantage with debulking nephrectomy in the cytokine era, and thus my opinoin is that debulking nephrectomy is the standard of care in appropriately selected patients. The phase 3 data and modern retrospective analyses in the TKI...
Which, if any, aspects of your management of prostate cancer differ in your African-American patients versus those of other racial/ethnic backgrounds?
My short answer is that I do not treat patients diagnosed with prostate cancer differently based on race or ethnicity. There is data to support a higher risk of progression on active surveillance among African American men as compared with Caucasian American men with low risk prostate cancer, but th...
In patients with Stage I seminoma who elect surveillance, how long do you recommend that tumor markers be followed?
I agree with @Dr. First Last that the data is vague. I would add the following: in series where patients are regularly re-staged with CT scans, serum tumor markers add essentially nothing. So if one follows the Princess Margaret Hospital schedule and gets scans every four months for the first 2 to 3...
For recurrent prostate cancer after definitive radiation, how do you guide patients between the various salvage options vs ADT?
This is a complex clinical situation and one needs to incorporate all available evidence regarding prior XRT details and PSA trajectory and imaging workup into the treatment decision. Below is the general strategy we use at Emory: For patients with rising PSA's post XRT, one should do a DRE, bone s...
What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?
As @Dr. First Last mentioned, the Messing randomized trial (ECOG 3886) showed that lifelong ADT (vs. observation) improved overall survival in patients with pN+ prostate cancer after radical prostatectomy. This trial provides the only level 1 evidence for this patient population. Therefore, ADT shou...
How would you manage a patient with stage I pure seminoma diagnosed incidentally after transscrotal orchiectomy?
For me, I would want to know the T stage and some other specifics about the case. The only option that I would not consider would be radiation therapy due to potential disruption of the usual dissemination paths. Surveillance with abdominal/pelvic CT scans would still be expected to catch relapse ea...
Is there a role for atezolizumab as a first-line agent for metastatic urothelial carcinomas?
The first question is whether the patient can tolerate cisplatin-based chemotherapy and whether or not they received (neoadjuvant or adjuvant) cisplatin-based chemotherapy within at least 1 year (if received peri-operative cisplatin-based therapy, it is a longer discussion regarding re-challenge tha...
Do you consider use of TIP as first-line therapy for poor-risk advanced germ cell tumors?
Unequivocally no. TIP seems clearly more toxic and achieves results no different than VIP or BEP given at high volume centers. TIP will not ever be compared to either and is going nowhere. In my view and the view of other testis cancer experts, the most important aspect is that these uncommon patien...
Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?
No, I generally do not counsel men about this risk. The two studies from the same investigator use a data warehouse search algorithm that may not be accurate enough to fully characterize who gets Alzheimer's disease or may not be able to correct for confounding factors that may be different between ...